Aberrant function of Smad2, a crucial member of transforming growth factor beta (TGF-β) signaling, is associated with the development of malignancies, particularly in the gastrointestinal district. However, little is known about its possible prognostic role in such tumor types. With the first meta-analysis on this topic, we demonstrated that the lack of the activated form of Smad2 (phosphor-Smad2 or pSmad2), which was meant to be the C-terminally phosphorylated form, showed a statistically significant association with an increased risk of all-cause mortality in patients with gastrointestinal cancers (RR, 1.58; 95% CI, 1.05–2.37, p = 0.029, I2 = 84%), also after having adjusted for potential confounders (RR, 1.65; 95% CI, 1.24–2.18; p < 0.001; I2 = 4%). This finding highlights the importance of the TGF-β signaling in this type of cancer. In this line, further studies are needed to explore more in depth this important molecular pathway, focusing also on potential therapeutic strategies based on its effectors or molecular targets. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.

Girolami, I., Veronese, N., Smith, L., Caruso, M., Reddavide, R., Leandro, G., et al. (2019). The activation status of the TGF-β transducer Smad2 is associated with a reduced survival in gastrointestinal cancers: A systematic review and meta-analysis [10.3390/ijms20153831].

The activation status of the TGF-β transducer Smad2 is associated with a reduced survival in gastrointestinal cancers: A systematic review and meta-analysis

Veronese, N.;
2019-01-01

Abstract

Aberrant function of Smad2, a crucial member of transforming growth factor beta (TGF-β) signaling, is associated with the development of malignancies, particularly in the gastrointestinal district. However, little is known about its possible prognostic role in such tumor types. With the first meta-analysis on this topic, we demonstrated that the lack of the activated form of Smad2 (phosphor-Smad2 or pSmad2), which was meant to be the C-terminally phosphorylated form, showed a statistically significant association with an increased risk of all-cause mortality in patients with gastrointestinal cancers (RR, 1.58; 95% CI, 1.05–2.37, p = 0.029, I2 = 84%), also after having adjusted for potential confounders (RR, 1.65; 95% CI, 1.24–2.18; p < 0.001; I2 = 4%). This finding highlights the importance of the TGF-β signaling in this type of cancer. In this line, further studies are needed to explore more in depth this important molecular pathway, focusing also on potential therapeutic strategies based on its effectors or molecular targets. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.
Girolami, I., Veronese, N., Smith, L., Caruso, M., Reddavide, R., Leandro, G., et al. (2019). The activation status of the TGF-β transducer Smad2 is associated with a reduced survival in gastrointestinal cancers: A systematic review and meta-analysis [10.3390/ijms20153831].
File in questo prodotto:
File Dimensione Formato  
ijms-20-03831.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 1.24 MB
Formato Adobe PDF
1.24 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/454003
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact